Six adenoviral vectored African swine fever virus genes protect against fatal disease caused by genotype I challenge.

Autor:	Portugal R; The Pirbright Institute, Woking, Surrey, United Kingdom., Goldswain H; The Pirbright Institute, Woking, Surrey, United Kingdom., Moore R; The Pirbright Institute, Woking, Surrey, United Kingdom., Tully M; The Pirbright Institute, Woking, Surrey, United Kingdom., Harris K; The Pirbright Institute, Woking, Surrey, United Kingdom., Corla A; The Pirbright Institute, Woking, Surrey, United Kingdom., Flannery J; The Pirbright Institute, Woking, Surrey, United Kingdom., Dixon LK; The Pirbright Institute, Woking, Surrey, United Kingdom., Netherton CL; The Pirbright Institute, Woking, Surrey, United Kingdom.
Jazyk:	angličtina
Zdroj:	Journal of virology [J Virol] 2024 Jul 23; Vol. 98 (7), pp. e0062224. Date of Electronic Publication: 2024 Jul 02.
DOI:	10.1128/jvi.00622-24
Abstrakt:	African swine fever virus causes a lethal hemorrhagic disease in domestic swine and wild boar for which currently licensed commercial vaccines are only available in Vietnam. Development of subunit vaccines is complicated by the lack of information on protective antigens as well as suitable delivery systems. Our previous work showed that a pool of eight African swine fever virus genes vectored using an adenovirus prime and modified vaccinia virus boost could prevent fatal disease after challenge with a virulent genotype I isolate of the virus. Here, we identify antigens within this pool of eight that are essential for the observed protection and demonstrate that adenovirus-prime followed by adenovirus-boost can also induce protective immune responses against genotype I African swine fever virus. Immunization with a pool of adenoviruses expressing individual African swine fever virus genes partially tailored to genotype II virus did not protect against challenge with genotype II Georgia 2007/1 strain, suggesting that different antigens may be required to induce cross-protection for genetically distinct viruses. Importance: African swine fever virus causes a lethal hemorrhagic disease in domestic pigs and has killed millions of animals across Europe and Asia since 2007. Development of safe and effective subunit vaccines against African swine fever has been problematic due to the complexity of the virus and a poor understanding of protective immunity. In a previous study, we demonstrated that a complex combination of eight different virus genes delivered using two different viral vector vaccine platforms protected domestic pigs from fatal disease. In this study, we show that three of the eight genes are required for protection and that one viral vector is sufficient, significantly reducing the complexity of the vaccine. Unfortunately, this combination did not protect against the current outbreak strain of African swine fever virus, suggesting that more work to identify immunogenic and protective viral proteins is required to develop a truly effective African swine fever vaccine. Competing Interests: C.L.N. and L.D.K. are named inventors on the patent WO/2021/019232 "African swine fever vaccine". The other authors declare no conflict of interest. The funders had no role in the design of the study, collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu